SCYX - SCYNEXIS INC

QQQ $ 617.50 $ 6.52 (1.07 %)

DIA $ 472.45 $ 4.92 (1.05 %)

SPY $ 677.25 $ 5.49 (0.82 %)

TLT $ 91.47 $ 0.04 (0.04 %)

GLD $ 378.59 $ -1.27 (-0.34 %)

Previous Close

$ 0.77

Open

$ 0.79

Bid

$ 0.76 x 200

Ask

$ 0.82 x 105

Day's Range

$ 0.77 - $ 0.80

52 Week Range

$ 0.66 - $ 1.49

Volume

268,379

Average Volume

Market Cap

32.28M

Beta (5Y Monthly)

$ 1.67

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-13-2025	06-30-2025	10-Q
2	05-15-2025	03-31-2025	10-Q
3	03-12-2025	12-31-2024	10-K
4	11-06-2024	09-30-2024	10-Q
5	08-08-2024	06-30-2024	10-Q
6	05-08-2024	03-31-2024	10-Q
7	03-28-2024	12-31-2023	10-K
8	11-13-2023	09-30-2023	10-Q
9	08-14-2023	06-30-2023	10-Q
10	05-10-2023	03-31-2023	10-Q
11	03-31-2023	12-31-2022	10-K
12	11-09-2022	09-30-2022	10-Q
13	08-15-2022	06-30-2022	10-Q
14	05-12-2022	03-31-2022	10-Q
15	03-29-2022	12-31-2021	10-K
16	11-10-2021	09-30-2021	10-Q
17	08-16-2021	06-30-2021	10-Q
18	05-17-2021	03-31-2021	10-Q
19	03-29-2021	12-31-2020	10-K
20	11-06-2020	09-30-2020	10-Q
21	08-10-2020	06-30-2020	10-Q
22	05-11-2020	03-31-2020	10-Q
23	03-11-2020	12-31-2019	10-K
24	11-12-2019	09-30-2019	10-Q
25	08-07-2019	06-30-2019	10-Q
26	05-08-2019	03-31-2019	10-Q
27	03-14-2019	12-31-2018	10-K
28	11-13-2018	09-30-2018	10-Q
29	08-09-2018	06-30-2018	10-Q
30	05-08-2018	03-31-2018	10-Q
31	03-13-2018	12-31-2017	10-K
32	11-07-2017	09-30-2017	10-Q
33	08-08-2017	06-30-2017	10-Q
34	05-08-2017	03-31-2017	10-Q
35	03-13-2017	12-31-2016	10-K
36	11-07-2016	09-30-2016	10-Q
37	08-08-2016	06-30-2016	10-Q
38	05-09-2016	03-31-2016	10-Q
39	03-07-2016	12-31-2015	10-K
40	11-13-2015	09-30-2015	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Trading Halt: Halt status updated at 8:20:...
10/15/2025 12:20:04

SCYNEXIS To Receive $22M From GlaxoSmithKl...
10/15/2025 12:08:33

SCYNEXIS to receive a $22 million payment as part of the resolution related to the restart of the Phase 3 MARIO study on invasi...

Trading Halt: Halted at 7:55:00 a.m. ET - ...
10/15/2025 11:55:04

12 Health Care Stocks Moving In Thursday's...
10/02/2025 12:09:25

12 Health Care Stocks Moving In Tuesday's ...
09/30/2025 21:06:48

12 Health Care Stocks Moving In Tuesday's ...
09/30/2025 17:06:34

SCYNEXIS Reports Results From Phase 1 Stud...
09/30/2025 12:07:48

No safety concerns or dose limiting toxicities observedSCY-247 was able to achieve target exposures at doses lower than our fir...

SCYNEXIS To Present At 12th Congress on Tr...
09/04/2025 12:38:56

SCYNEXIS Q2 EPS $(0.14) Beats $(0.19) Esti...
08/13/2025 20:34:53

SCYNEXIS (NASDAQ:SCYX) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.19) by 2...

SCYNEXIS Announces Nasdaq Noncompliance Le...
06/26/2025 20:04:59

-SEC Filing

SCYNEXIS Resumes Patient Dosing In Phase 3...
05/28/2025 12:35:22

SCYNEXIS Q1 EPS $(0.11) Beats $(0.17) Esti...
05/15/2025 20:50:34

SCYNEXIS (NASDAQ:SCYX) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.17) by 3...

SCYNEXIS To Present Preclinical Data On Se...
04/08/2025 12:57:32

SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-trea...

SCYNEXIS 2024 GAAP EPS $(0.44) Down From $...
03/12/2025 21:19:44

SCYNEXIS Initiates Dosing In Phase 1 Trial...
12/18/2024 13:16:28

SCYNEXIS Q3 EPS $(0.06) Beats $(0.07) Esti...
11/06/2024 22:27:11

SCYNEXIS (NASDAQ:SCYX) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.07) by 1...

SCYNEXIS To Present Preclinical Data On Se...
10/03/2024 12:21:56

SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-trea...

SCYNEXIS Q1 2024 GAAP EPS $0.01 Beats $(0....
05/08/2024 22:37:31

SCYNEXIS (NASDAQ:SCYX) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.20) by 1...

SCYNEXIS Presented Preclinical Data On Sec...
04/30/2024 20:39:47

In vivo data demonstrated efficacy of SCY-247 in mouse model of invasive candidiasis caused by Candida glabrata SCY-247 showed ...

Cantor Fitzgerald Reiterates Overweight on...
04/01/2024 12:31:45

Cantor Fitzgerald analyst Louise Chen reiterates SCYNEXIS (NASDAQ:SCYX) with a Overweight.